RE: New genotyping for Mavacamten treatment announced!!20 Dec 2024 07:24
In the July RNS on the final NICE recommendation for the stroke test, there was the following statement:
Whilst positioned primarily for enabling near-patient testing, the Genedrive® System is also suitable for traditional laboratory testing paradigms as a more affordable alternative to laboratory platforms where sample throughput requirements do not necessitate high-scale batch processing.